Myriad Genetics, Inc. (MYGN) - Financial and Strategic SWOT Analysis Review

Document Sample
Myriad Genetics, Inc. (MYGN) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					          Myriad Genetics, Inc. (MYGN) - Financial and Strategic SWOT Analysis
                                         Review
        Reference Code: GDPH7218FSA                                                                                                                           Publication Date: JAN 2014

       Table of Contents
       Table of Contents ............................................................................................................................................................................... 1
          List of Tables .................................................................................................................................................................................. 3
          List of Figures ................................................................................................................................................................................. 3
       Section 1 - About the Company.......................................................................................................................................................... 5
       Myriad Genetics, Inc. - Key Facts....................................................................................................................................................... 5
       Myriad Genetics, Inc. - Key Employees .............................................................................................................................................. 6
       Myriad Genetics, Inc. - Key Employee Biographies ............................................................................................................................ 7
       Myriad Genetics, Inc. - Major Products and Services ......................................................................................................................... 8
       Myriad Genetics, Inc. - Medical Equipment Pipeline Products Data ................................................................................................... 9
          Myriad Genetics, Inc. Pipeline Products by Equipment Type.......................................................................................................... 9
          Myriad Genetics, Inc. Pipeline Products by Development Stage .................................................................................................. 11
       Myriad Genetics, Inc. - History ......................................................................................................................................................... 13
       Myriad Genetics, Inc. - Company Statement .................................................................................................................................... 18
       Myriad Genetics, Inc. - Locations And Subsidiaries ......................................................................................................................... 20
          Head Office ................................................................................................................................................................................... 20
          Other Locations & Subsidiaries ..................................................................................................................................................... 20
       Section 2 – Company Analysis ......................................................................................................................................................... 21
       Myriad Genetics, Inc. - Business Description ................................................................................................................................... 21
       Myriad Genetics, Inc. - Corporate Strategy ...................................................................................................................................... 22
       Myriad Genetics, Inc. - SWOT Analysis............................................................................................................................................ 23
          SWOT Analysis - Overview........................................................................................................................................................... 23
          Myriad Genetics, Inc. - Strengths .................................................................................................................................................. 23
             Strength - Product & Service Portfolio ....................................................................................................................................... 23
             Strength - Multiple Companion Diagnostic Partnerships ........................................................................................................... 23
             Strength - Expanding Operating Margin .................................................................................................................................... 23
          Myriad Genetics, Inc. - Weaknesses ............................................................................................................................................ 23
             Weakness - Single Laboratory Facility ...................................................................................................................................... 23
             Weakness - Limited Liquidity Position ....................................................................................................................................... 23
          Myriad Genetics, Inc. - Opportunities ............................................................................................................................................ 24
             Opportunity - Product Pipeline .................................................................................................................................................. 24
             Opportunity - Growing Prostate Cancer Market ........................................................................................................................ 24
          Myriad Genetics, Inc. - Threats ..................................................................................................................................................... 24
             Threat - Intense Competition ..................................................................................................................................................... 24
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 24
             Threat - Stringent Government Regulations .............................................................................................................................. 24
       Myriad Genetics, Inc. - Key Competitors .......................................................................................................................................... 25
       Section 3 – Company Financial Ratios ............................................................................................................................................. 26
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 26
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 26
       Performance Chart ........................................................................................................................................................................... 28
       Financial Performance...................................................................................................................................................................... 28


Myriad Genetics, Inc. (MYGN) - Financial and Strategic SWOT                                                                                                      Reference Code: GDPH7218FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Financial Ratios - Interim Ratios....................................................................................................................................................... 29
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 30
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 31
          Myriad Genetics, Inc., Medical Equipment, Deals By Year, 2008 to YTD 2014 ............................................................................ 31
          Myriad Genetics, Inc., Medical Equipment, Deals By Type, 2008 to YTD 2014............................................................................ 32
          Myriad Genetics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 .......................................................... 33
          Myriad Genetics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014 .......................................................... 34
       Myriad Genetics, Inc., Recent Deals Summary ................................................................................................................................ 35
       Section 5 – Company’s Recent Developments ................................................................................................................................ 36
          Myriad Genetics, Inc., Recent Developments ............................................................................................................................... 36
             Jan 07, 2014: Myriad Genetics to Present at the 32nd Annual J.P. Morgan Healthcare Conference ....................................... 36
             Dec 05, 2013: Myriad Genetics Announces Upcoming Investor Event ..................................................................................... 36
             Nov 27, 2013: Invitae Responds to Myriad Genetics Lawsuit ................................................................................................... 36
             Nov 05, 2013: Myriad Genetics Reports Financial Results for First Quarter of Fiscal Year 2014 ............................................. 37
             Oct 23, 2013: Myriad Genetics to Announce Fiscal First Quarter 2014 Financial Results on Tuesday November 5, 2013 ...... 38
             Oct 22, 2013: BioReference Laboratories Sued by Myriad Genetics, Confident in Its Position ................................................. 38
             Sep 05, 2013: Myriad Genetics to Present at the Morgan Stanley Global Healthcare Conference ........................................... 38
             Aug 16, 2013: Gene By Gene Rejects BRCA1/2 Patent Infringement Claims by Myriad and Joins Ambry Genetics to Sue
             Myriad for Violating Federal Antitrust Laws ............................................................................................................................... 39
             Aug 13, 2013: Myriad Genetics Reports Full-Year and Fiscal Fourth-Quarter 2013 Financial Results ..................................... 39
             Aug 06, 2013: Ambry Genetics Sues Myriad Genetics for Violating Federal Antitrust Laws ..................................................... 40
       Section 6 – Appendix ....................................................................................................................................................................... 42
          Methodology ................................................................................................................................................................................. 42
          Ratio Definitions .
				
DOCUMENT INFO
Description: Myriad Genetics, Inc. (MYGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including: - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competitors – A list of key competitors to the company. - Key employees – A list of the key executives of the company. - Executive biographies – A brief summary of the executives’ employment history. - Key operational heads – A list of personnel heading key departments/functions. - Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company. - Key manufacturing facilities – A list of key manufacturing facilities of the company. - Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Highlights Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The company undertakes the d
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.